The latest ranking of pharmaceutical companies announced (with list)

There are 5 Chinese pharmaceutical companies on the list this time, namely: Yunnan Baiyao, Hengrui Pharmaceuticals, China Biopharmaceuticals, Shanghai Pharmaceuticals, and CSPC, with the largest number in history
.

Among these 50 companies, three are new faces.
In addition to CSPC, there are Huizhi (No.
19) formed by the merger of Mylan and Pfizer Propulsion, and German STADA Arzneimittel (No.
50)
.

2.
Five Chinese pharmaceutical companies are on the list

In 2019, Chinese pharmaceutical companies appeared for the first time in the TOP50 list of global pharmaceutical companies.
Two of them were on the list, reaching four in 2020.
By 2021, a total of five Chinese pharmaceutical companies have been selected, and the number has increased year by year
.

The companies on this list are Yunnan Baiyao (34th, US$4.
741 billion), Hengrui Pharmaceuticals (38th, US$4.
203 billion), China Biopharmaceuticals (40th, US$3.
893 billion), Shanghai Pharmaceuticals (42nd, US$3.
893 billion).
Name, 3.
585 billion U.
S.
dollars) and CSPC (44th, 3.
242 billion U.
S.
dollars)
.

Among them, Hengrui and China Biopharmaceutical have been on the list for the third time
.

In recent years, Hengrui Pharmaceuticals has always attached great importance to innovative research and development, and R&D investment has been increasing year by year
.

In 2021, the newly-listed CSPC Group's prescription drug revenue was US$3.
242 billion, and its full-year revenue in 2020 was 24.
94 billion yuan, an increase of 12.
8% year-on-year, and its net profit was RMB 5.
16 billion, an increase of 38.
9% year-on-year
.

Enbipu (Butylphthalide), Celiac (Albumin Paclitaxel), Domesol (Doxorubicin Hydrochloride) are currently CSPC's main profit contribution sources
.

CSPC has also focused on the research and development of new drugs in recent years.
In 2020, the research and development expenses will be 2.
89 billion yuan, a year-on-year increase of 44.
5%
.

In general, with the high-quality development of the domestic pharmaceutical industry, it is believed that more and more Chinese companies will be on the list in the future
.

3.
The epidemic has become the biggest factor

Compared with 2019, "2021 Pharm Exec50" believes that the factor that has the greatest impact on pharmaceutical companies in 2020 is the new crown epidemic
.

According to a survey conducted by Model N, 58% of executives said that the pandemic had a great impact on them
.

However, as a whole, despite the impact of the new crown, six of the top ten in this list remain unchanged and have little change
.

Last year, Roche topped the list with sales of 48.
247 billion U.
S.
dollars, ending Pfizer's previous four consecutive years of "dominance".
This year, although its prescription drug revenue has fallen by 1.
6%, it still remains the number one position
.

It is understood that the decline in sales of Avastin, Herceptin, and Rituxan troika is due to the impact of biosimilar drugs and the impact of the new crown epidemic, but there are still other products in the Roche tumor pipeline
.
For example, three products, Tecentriq, Perjeta, and Kadcyla, are known as the new "troika" of Roche's oncology business due to their outstanding sales performance
.
In addition to the oncology business, blockbuster products such as Ocrevus are also important supplements to Roche's product line
.

Since AbbVie completed the acquisition of Allergan in May 2020, its volume has soared from 33.
266 billion U.
S.
dollars in 2019 to 45.
804 billion U.
S.
dollars, surpassing Pfizer after divesting assets and slimming, rising from 8th to No.
3 people
.
At present, Humira is still AbbVie's revenue pillar, contributing US$19.
832 billion, accounting for about 45% of AbbVie’s total drug sales, and one of the largest single drug shares among large pharmaceutical companies
.

However, Humira will lose its global market exclusivity in 2023, and AbbVie hopes that its next-generation drugs Skyrizi and Rinvoq will fill the gap after the patent
.
These two drugs have been approved to treat psoriasis and rheumatoid arthritis, respectively, with combined sales of US$2 billion in 2020
.
In addition, neurological disease products such as Vraylar (cariprazine), new migraine drug Ubrelvy (ubrogepant), and products such as Imbruvica (ibrutinib) and Venclexta (Venclexta) in the oncology field are also expected to become important pillars of future performance.

.

Generally speaking, some insiders believe that the acquisition of Allergan has greatly enriched AbbVie's product line and got rid of the excessive dependence on Humira in the past
.